{
  "id": "4abe48e8b1166d90",
  "title": "Eisai : Biologics License Application for Subcutaneous Formulation of LEQEMBI ( R ) ( lecanemab ) for the Treatment of Early Alzheimer Disease Designated for Priority Review in China",
  "description": "20260210T080000Z",
  "content": "",
  "source": "finanznachrichten.de",
  "source_url": "https://www.finanznachrichten.de/nachrichten-2026-02/67657382-eisai-biologics-license-application-for-subcutaneous-formulation-of-leqembi-r-lecanemab-for-the-treatment-of-early-alzheimer-s-disease-designate-011.htm",
  "published_at": "20260210T080000Z",
  "fetched_at": "2026-02-11T00:34:18.892628+00:00",
  "category": "health_biotech",
  "subcategory": null,
  "keywords": [
    "china",
    "ai"
  ],
  "location": "Germany",
  "raw_data": {
    "url": "https://www.finanznachrichten.de/nachrichten-2026-02/67657382-eisai-biologics-license-application-for-subcutaneous-formulation-of-leqembi-r-lecanemab-for-the-treatment-of-early-alzheimer-s-disease-designate-011.htm",
    "url_mobile": "",
    "title": "Eisai : Biologics License Application for Subcutaneous Formulation of LEQEMBI ( R ) ( lecanemab ) for the Treatment of Early Alzheimer Disease Designated for Priority Review in China",
    "seendate": "20260210T080000Z",
    "socialimage": "https://www.finanznachrichten.de/chart-eisai-co-ltd-aktie-intraklein-tradegate.png",
    "domain": "finanznachrichten.de",
    "language": "English",
    "sourcecountry": "Germany"
  }
}